Logo

American Heart Association

  13
  0


Final ID: MP2049

A Contemporary Machine Learning-Based Risk Stratification for Mortality and Hospitalization in Heart Failure with Preserved Ejection Fraction Using Multimodal Real-World Data

Abstract Body (Do not enter title and authors here):
Background: Heart failure with preserved ejection fraction (HFpEF) is a heterogeneous condition with high morbidity and mortality. Risk stratification of patients with HFpEF is important for advancing therapeutic development and improving clinical care.
Research question: Predicting overall mortality and heart failure (HF) Hospitalization in real world HFpEF population
Aims : to leverage machine learning model to develop prognostic models based on real-world data, with the potential to support risk stratification in routine clinical practice
Methods: CONFIDENT is an observational, multi-cohort study across three centers in Europe and the US. Patients with HFpEF, according to the HFA-PEFF criteria with ≥ 2 years of follow-up, were included from 2013 to 2022. The dataset included multimodal data from electronic health records, lab tests, echocardiography, and electrocardiography, with 82 baseline candidate variables. We developed machine learning-based prognostic models to predict all-cause mortality and HF hospitalization. Model performance was compared to conventional risk score in an external validation cohort.
Results: A total of 1208 patients were included in the study. The mean age was 72±12. The 2-year risk of HF hospitalization and all-cause mortality ranged from 13 to 44% and 9 to 19% respectively. The all-cause mortality prognostic model achieved good discrimination with a C-index of 0.67 [95%CI, 0.66-0.68], and 0.68 [95%CI 0.66-0.69] in the training cohorts, and 0.72 [95%CI 0.65-0.78] in the validation cohort, and performed better than the PREDICT-HFpEF score (C-index: 0.66 [95%CI 0.65-0.68], p-value =0.012; 0.60, [95%CI 0.59-0.62],p-value < 0.01 and 0.67 [95%CI 0.58-0.73], p-value =0.013 respectively. Similar results were observed when compared to the Meta-Analysis Global Group In Chronic Heart Failure Risk Score (MAGGIC). Similarly, the model derived for HF hospitalization outperformed PREDICT-HFpEF and MAGGIC + natriuretic peptide.
Conclusion: CONFIDENT prognostic models for all-cause mortality and HF hospitalization using routinely collected variables can reliably predict outcomes and facilitate personalized care and trial recruitment strategies in HFpEF.
  • Fudim, Marat  ( Duke Clinical Research Institute , Hillsborough , North Carolina , United States )
  • Weerts, Jerremy  ( University Hospital Maastricht , Maastricht , Netherlands )
  • Patel, Manesh  ( DUKE MEDICAL CENTER , Durham , North Carolina , United States )
  • Balu, Suresh  ( Duke University , Durham , North Carolina , United States )
  • Hintze, Bradley  ( Duke University , Durham , North Carolina , United States )
  • Torres, Francisco  ( Owkin , Paris , France )
  • Micsinai Balan, Mariann  ( Bristol Myers Squibb , San Diego , California , United States )
  • Rigolli, Marzia  ( Bristol Myers Squibb , San Diego , California , United States )
  • Kessler, Paul  ( Bristol Myers Squibb , San Diego , California , United States )
  • Touzot, Maxime  ( Owkin , Paris , France )
  • Lund, Lars  ( Karolinska , Stockholm , Sweden )
  • Van Empel, Vanessa  ( University Hospital Maastricht , Maastricht , Netherlands )
  • Pradhan, Aruna  ( Bristol Myers Squibb , Newton , Massachusetts , United States )
  • Butler, Javed  ( Baylor Scott & White Research Institute , Dallas , Texas , United States )
  • Zehnder, Tobias  ( Owkin , Paris , France )
  • Sauty, Benoit  ( Owkin , Paris , France )
  • Esposito, Christian  ( Owkin , Paris , France )
  • Balazard, Félix  ( Owkin , Paris , France )
  • Mayer, Imke  ( Owkin , Paris , France )
  • Hallal, Mohammad  ( Owkin , Paris , France )
  • Loiseau, Nicolas  ( Owkin , Paris , France )
  • Author Disclosures:
    Marat Fudim: DO have relevant financial relationships ; Consultant:Alleviant:Active (exists now) ; Consultant:Lumia:Active (exists now) ; Consultant:Abbott:Active (exists now) ; Consultant:Medtronic:Active (exists now) ; Consultant:BSC:Active (exists now) | Jerremy Weerts: DO have relevant financial relationships ; Other (please indicate in the box next to the company name):Corvia Medical; grant:Past (completed) ; Other (please indicate in the box next to the company name):Boehringer Ingelheim; grant:Past (completed) ; Other (please indicate in the box next to the company name):CSL Vifor; grant:Past (completed) | Manesh Patel: DO have relevant financial relationships ; Consultant:Bayer:Past (completed) ; Consultant:Janssen:Past (completed) ; Consultant:Esperon:Past (completed) ; Researcher:Idorsia:Active (exists now) ; Researcher:Regeneron:Active (exists now) ; Researcher:Bayer:Past (completed) | Suresh Balu: DO have relevant financial relationships ; Individual Stocks/Stock Options:CohereMed Inc.:Active (exists now) ; Individual Stocks/Stock Options:Fullsteam Health:Active (exists now) | Bradley Hintze: DO NOT have relevant financial relationships | Francisco Torres: No Answer | Mariann Micsinai Balan: No Answer | Marzia Rigolli: No Answer | Paul Kessler: No Answer | Maxime TOUZOT: DO NOT have relevant financial relationships | Lars Lund: DO NOT have relevant financial relationships | Vanessa van Empel: No Answer | Aruna Pradhan: DO have relevant financial relationships ; Employee:Bristol Myers Squibb:Active (exists now) | Javed Butler: No Answer | Tobias Zehnder: DO have relevant financial relationships ; Employee:Owkin:Active (exists now) | Benoit Sauty: No Answer | Christian Esposito: No Answer | Félix Balazard: DO have relevant financial relationships ; Employee:Owkin:Active (exists now) ; Employee:Sanofi:Expected (by end of conference) ; Individual Stocks/Stock Options:Owkin:Active (exists now) | Imke Mayer: DO have relevant financial relationships ; Employee:Owkin:Active (exists now) ; Other (please indicate in the box next to the company name):BMS (analyst for project with Owkin):Past (completed) | Mohammad Hallal: DO have relevant financial relationships ; Employee:Owkin:Active (exists now) | Nicolas Loiseau: No Answer
Meeting Info:

Scientific Sessions 2025

2025

New Orleans, Louisiana

Session Info:

Heart Failure and Cardiomyopathy: Disease Management and Outcomes

Monday, 11/10/2025 , 12:15PM - 01:10PM

Moderated Digital Poster Session

More abstracts on this topic:
A Meta-Analysis of Prospective Studies Comparing Short and Longterm Outcomes of Trans-Catheter Aortic Valve Replacement in Patient with and without Cancer:

Khan Muhammad Aslam, Haider Adnan, Haider Taimoor, Bhattarai Shraddha, Khan Bilal, Lamichhane Bikal, Shafique Nouman, Rahman Hammad, Aafreen Asna, Muhammad Anza, Bhatia Hitesh, Khan Abid Nawaz Khan, Akbar Usman, Khan Alamzaib

6-Nitrodopamine potentiates the positive chronotopic and inotropic effect induced by noradrenaline in the rat isolated heart

Lima Antonio, Sobanski Joao Fernando, Antunes Edson, De Nucci Gilberto

More abstracts from these authors:
Investigating the natural history and risk factors underlying deterioration in early-stage hypertrophic cardiomyopathy: findings from SOLENOID

Bradlow William, Guichard Ninon, Jaeger Alexandre, Micsinai Balan Mariann, Simon Antoine, Sehnert Amy, Touzot Maxime, Bastien Arnaud, Charron Philippe, Elgui Kevin, Ducret Valerie, Trichelair Paul, Chevalier Philippe, Ripoll Tomas, Fudim Marat, Patel Manesh, Deleforge Aurelie

Beta blockers and calcium channel blockers in pre-symptomatic patients with hypertrophic cardiomyopathy: prevalence, discontinuation, and effectiveness

Bradlow William, Sehnert Amy, Bastien Arnaud, Blizard Perry, Ripoll-vera Tomas, Pericas Pau, Fudim Marat, Balu Suresh, Hintze Bradley, Salah Husam, Patel Manesh, Elgui Kevin, Foucher Aurelie, Charron Philippe, Klopfenstein Quentin, Balazard Felix, Trichelair Paul, Touzot Maxime, Micsinai Balan Mariann, Van Haelst Paul, Sandler Belinda

You have to be authorized to contact abstract author. Please, Login
Not Available